Provider Briefing: Afrezza Availability in 2026

If you prescribe Afrezza (Insulin Human Inhalation Powder) for your patients with diabetes, you've likely heard the complaint: "My pharmacy can't get it." This issue has persisted for years and continues into 2026. Understanding the current supply landscape, cost considerations, and practical solutions is essential for advising your patients effectively.

This article provides a comprehensive overview of Afrezza's availability status, the factors behind access barriers, and the tools and resources you can use to help your patients get their medication.

Timeline: Afrezza's Availability History

Afrezza has had a unique commercial history since its FDA approval in June 2014:

• 2014: FDA approves Afrezza (MannKind Corporation/Sanofi-Aventis partnership) for adult patients with type 1 and type 2 diabetes.
• 2016: Sanofi ends its partnership with MannKind. MannKind assumes full responsibility for distribution and launches patient reimbursement and adherence support programs.
• 2016-2020: Slow commercial adoption due to prescriber unfamiliarity, insurance barriers, and limited pharmacy stocking. MannKind launches direct-to-patient program via Eagle Pharmacy.
• 2021-2023: Increased patient interest driven by growing awareness of inhaled insulin benefits and expansion of MannKind's savings programs. Medicare $35 insulin cap takes effect in 2023 under the Inflation Reduction Act.
• 2024-2026: Afrezza remains commercially available with no reported manufacturing shortage. Distribution challenges persist due to low pharmacy stocking rates and single-source manufacturing.

Current Supply Status

As of early 2026, Afrezza is not listed on the FDA or ASHP drug shortage databases. MannKind Corporation continues to manufacture and distribute all three cartridge strengths (4-unit, 8-unit, and 12-unit) and the Afrezza Inhaler.

The supply challenges reported by patients are distribution- and stocking-related rather than manufacturing-related. Key factors include:

• Single-source supply: MannKind is the sole manufacturer. There are no generic, biosimilar, or authorized generic alternatives.
• Low pharmacy penetration: Most retail chain pharmacies (CVS, Walgreens, Rite Aid) do not routinely stock Afrezza due to low per-location demand.
• Specialty handling: Afrezza requires refrigeration for unopened cartridges and proper storage protocols that may deter some pharmacies.

Prescribing Implications

When prescribing Afrezza, several clinical and practical considerations impact patient access:

Prior Authorization and Step Therapy

The majority of commercial payers and Medicare Part D plans require prior authorization for Afrezza. Many also impose step therapy, requiring documentation that the patient has tried and inadequately responded to at least one injectable rapid-acting insulin (e.g., Insulin Lispro, Insulin Aspart) before approving Afrezza.

Clinical documentation should include:

• Rationale for inhaled insulin (e.g., needle phobia, injection site issues, patient preference impacting adherence)
• Prior injectable insulin history and reasons for inadequate response
• Spirometry results (FEV1) documenting the absence of chronic lung disease
• Smoking status confirmation

Contraindications to Review

Before prescribing, ensure your patient does not have any contraindications:

• Chronic lung disease: Afrezza carries a boxed warning for risk of acute bronchospasm in patients with asthma, COPD, or other chronic lung conditions. It is contraindicated in these patients.
• Smoking: Safety and efficacy have not been established in patients who smoke or have recently quit. Use is not recommended.
• Baseline spirometry: FEV1 testing is required before initiating therapy and recommended periodically thereafter.

For complete prescribing details including drug interactions and side effect management, refer to the full prescribing information.

Availability Picture: Where Patients Can Fill

Understanding the distribution landscape helps you set patient expectations and guide them to successful fills:

• Chain pharmacies: Most do not routinely stock Afrezza but can special-order through wholesalers (1-3 business day turnaround).
• Independent pharmacies: Often more willing to maintain standing orders for individual patients. Diabetes-focused independents may already carry it.
• Specialty pharmacies: The most reliable source for consistent Afrezza supply. Many endocrinology practices have established relationships with specialty pharmacies that handle inhaled insulin.
• Mail-order pharmacies: Available through some insurance plans for 90-day supply delivery.
• MannKind Direct Purchase: Cash-paying patients can receive Afrezza shipped to their home for as low as $99/month through Eagle Pharmacy (844-323-7399).

Cost and Access in 2026

Cost remains a significant barrier for many patients. Here is the current pricing landscape:

Cash Pricing

• 4-unit cartridges (90 count): ~$470
• Combination packs (180 count): $1,396 - $2,321 depending on dose combination
• MannKind Direct Purchase: $99/month

Insurance Coverage

• Commercial plans: Most cover with prior authorization. Afrezza Savings Card reduces copay to as little as $35/fill (up to $2,000/year savings, 12 fills).
• Medicare Part D: Covered with $35/month copay cap under the Inflation Reduction Act. Prior authorization typically required.
• Medicaid: Coverage varies by state. Many state Medicaid programs require prior authorization.

Patient Assistance

• Patient Access Network Foundation (PAN): For insured patients at 400-500% of FPL.
• MannKind Direct Purchase Program: $99/month for cash-paying patients.
• NeedyMeds and RxAssist directories list additional assistance options.

Direct patients to our guide on saving money on Afrezza for comprehensive cost-reduction strategies.

Tools and Resources for Providers

Several resources can help streamline the prescribing and filling process for your Afrezza patients:

• Medfinder for Providers: Help patients find pharmacies that have Afrezza in stock near them. Integrate this tool into your patient education workflow.
• MannKind support: Call 844-323-7399 for prescriber support, including prior authorization assistance and patient enrollment in savings programs.
• Specialty pharmacy referrals: Establish a relationship with one or two specialty pharmacies that consistently stock Afrezza. Share this information with your patients at the time of prescribing.
• Prior authorization templates: Prepare standardized prior authorization documentation including clinical rationale, spirometry results, and prior insulin history to reduce turnaround time.

Looking Ahead

As of 2026, there are no FDA-approved competitors to Afrezza in the inhaled insulin space, and no generic or biosimilar versions are expected in the near term due to the proprietary Technosphere technology.

The closest injectable alternative remains Lyumjev (Insulin Lispro-aabc), an ultra-rapid-acting insulin with onset comparable to (though not quite as fast as) Afrezza. It may serve as a bridge therapy for patients who cannot access Afrezza or have contraindications to inhaled insulin.

MannKind continues to expand its direct-to-patient infrastructure, which may help ease distribution bottlenecks over time. Providers who proactively connect patients with specialty pharmacies, savings programs, and tools like Medfinder can significantly reduce the access burden their patients face.

Final Thoughts

Afrezza offers a unique therapeutic option — ultra-rapid onset, needle-free delivery, and a pharmacokinetic profile that closely mimics physiologic insulin release. But its single-manufacturer status, specialty pharmacy requirements, and insurance barriers create real access challenges for patients.

As a prescriber, you can make a meaningful difference by:

1. Setting expectations at the time of prescribing about potential pharmacy availability issues
2. Providing prior authorization documentation proactively
3. Connecting patients with specialty pharmacies and the MannKind Direct Purchase Program
4. Directing patients to Medfinder for real-time pharmacy availability

Your patients chose Afrezza for a reason. Helping them actually access it is part of the care.